Effects of thalidomide in experimental models of post-endoscopic retrograde cholangiopancreatography pancreatitis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 22, Issue 3, 2007, Pages 371-376

  Xiong, Guang Su ^a   Wu, Shu Ming ^a,b   Wang, Zhen Hua ^a   Mo, Jian Zhong ^a   Xiao, Shu Dong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Endoscopic retrograde cholangiopancreatography; Pancreatitis; Thalidomide; Tumor necrosis factor

Indexed keywords

AMYLASE; MESSENGER RNA; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

AMYLASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; EDEMA; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; GENE EXPRESSION; HISTOLOGY; MALE; NONHUMAN; PANCREATITIS; PRIORITY JOURNAL; RAT; RNA DEGRADATION;

EID: 33846932339     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2006.04552.x     Document Type: Article

References (32)

1. Freeman ML, Nelson DB, Sherman S et al. Complications of endoscopic biliary sphincterotomy. N. Engl. J. Med. 1996; 335: 909-18.
2. Sherman S, Ruffolo TA, Hawes RH, Lehman GA. Complications of endoscopic sphincterotomy. A prospective series with emphasis on the increased risk associated with sphincter of Oddi dysfunction and nondilated bile ducts. Gastroenterology 1991; 101: 1068-75.
3. Cavallini G, Tittobello A, Frulloni L, Masci E, Mariana A, Di Francesco V. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy - Italian Group. N. Engl. J. Med. 1996; 335: 919-23.
4. Sand J, Nordback I. Prospective randomized trial of the effect of nifedipine on pancreatic irritation after endoscopic retrograde cholangiopancreatography. Digestion 1993; 54: 105-11.
5. He ZJ, Winston JH, Yusuf TE et al. Intraductal administration of an NK1 receptor antagonist attenuates the inflammatory response to retrograde infusion of radiological contrast in rats: implications for the pathogenesis and prevention of ERCP-induced pancreatitis. Pancreas 2003; 27: e13-17.
6. Kusske AM, Rongione AJ, Reber HA. Cytokines and acute pancreatitis. Gastroenterology 1996; 110: 639-42.
7. Hughes CB, Gaber LW, Kotb M, Mohey el-Din AB, Pabst M, Gaber AO. Induction of acute pancreatitis in germ-free rats: evidence of a primary role for tumor necrosis factor-alpha. Surgery 1995; 117: 201-5.
8. Hughes CB, Grewal HP, Gaber LW et al. Anti-TNFalpha therapy improves survival and ameliorates the pathophysiologic sequelae in acute pancreatitis in the rat. Am. J. Surg. 1996; 171: 274-80.
9. Oruc N, Ozutemiz AO, Yukselen V et al. Infliximab: a new therapeutic agent in acute pancreatitis? Pancreas 2004; 28: e1-8.
10. Kivisaari L. Contrast absorption and pancreatic inflammation following experimental ERCP. Invest. Radiol. 1979; 14: 493-7.
11. Xiong G, Wu S, Xie H, Chen X, Zhi L. A model of post-ERCP pancreatitis in rats. Chin. J. Pancreatol. 2004; 4: 231-3.
12. Schmidt J, Rattner DW, Lewandrowski K et al. A better model of acute pancreatitis for evaluating therapy. Ann. Surg. 1992; 215: 44-56.
13. Mikami K, Otaka M, Goto T et al. Induction of a 72-kDa heat shock protein and protection against lipopolysaccharide-induced liver injury in cirrhotic rats. J. Gastroenterol. Hepatol. 2004; 19: 884-90.
14. Freeman ML. Prevention of post-ERCP pancreatitis: pharmacologic solution or patient selection and pancreatic stents? Gastroenterology 2003; 124: 1977-80.
15. Pande H, Thuluvath P. Pharmacological prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis. Drugs 2003; 63: 1799-812.
16. Norman JG, Fink GW, Franz MG. Acute pancreatitis induces intrapancreatic tumor necrosis factor gene expression. Arch. Surg. 1995; 130: 966-70.
17. Grewal HP, Kotb M, el Din AM et al. Induction of tumor necrosis factor in severe acute pancreatitis and its subsequent reduction after hepatic passage. Surgery 1994; 115: 213-21.
18. Teo SK, Stirling DI, Zeldis JB. Thalidomide as a novel therapeutic agent: new uses for an old product. Drug Discov. Today 2005; 10: 107-14.
19. Corral LG, Muller GW, Moreira AL et al. Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity. Mol. Med. 1996; 2: 506-15.
20. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J. Exp. Med. 1993; 177: 1675-80.
21. Corral LG, Haslett PA, Muller GW et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J. Immunol. 1999; 163: 380-6.
22. Keifer JA, Guttridge DC, Ashburner BP, Baldwin AS Jr. Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J. Biol. Chem. 2001; 276: 22 382-7.
23. Hideshima T, Chauhan D, Shima Y et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000; 96: 2943-50.
24. Mitsiades N, Mitsiades CS, Poulaki V et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002; 99: 4525-30.
25. Payvandi F, Wu L, Haley M et al. Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-alpha, IL-1beta, and LPS-stimulated human PBMC in a partially IL-10-dependent manner. Cell. Immunol. 2004; 230: 81-8.
26. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl Acad. Sci. USA 1994; 91: 4082-5.
27. Dredge K, Marriott JB, Macdonald CD et al. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br. J. Cancer 2002; 87: 1166-72.
28. Akashi R, Kiyozumi T, Tanaka T, Sakurai K, Oda Y, Sagara K. Mechanism of pancreatitis caused by ERCP. Gastrointest. Endosc. 2002; 55: 50-4.
29. Marks JM, Dunkin BJ, Shillingstad BL et al. Pretreatment with allopurinol diminishes pancreatography-induced pancreatitis in a canine model. Gastrointest. Endosc. 1998; 48: 180-3.
30. Bub H, Burner W, Riemann JF, Stolte M. Morphology of the pancreatic ductal epithelium after traumatization of the papilla of Vater or endoscopic retrograde pancreatography with various contrast media in cats. Scand. J. Gastroenterol. 1983; 18: 581-92.
31. Ohlsson K, Olsson R, Bjork P et al. Local administration of human pancreatic secretory trypsin inhibitor prevents the development of experimental acute pancreatitis in rats and dogs. Scand. J. Gastroenterol. 1989; 24: 693-704.
32. Wakayama T, Itoh T, Shibayama K, Idezuki Y. Prevention of the spread of experimental acute pancreatitis by intraductal administration of a synthetic protease inhibitor in dogs. Am. J. Gastroenterol. 1989; 84: 272-8.